In China, the enrolment rate of single-country trials far exceeds that of multinational trials in every phase (Figure 1). GlobalData looked at trials between January 2001 and April 2018 and found the rate was 12 times higher in single-country trials in Phase II and seven times higher in Phase I and Phase III trials. The much higher enrolment rate in single-country trials can be attributed to the single regulatory and ethical authority, as well as the availability of subjects meeting the inclusion criteria for trials.
Figure 1: Enrolment rate by phase in multinational and single-country trials in China
|Source: GlobalData ©GlobalData|